Current Clinical Trials

Phase 1b Study of ASP1951, a GITR Agonistic Antibody, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

An open-Label Study Of ALPN-202 In Subjects With Advanced Malignancies (NEON-1)

Phase 1 Study of the safety, Pharmacokinetic and Pharmacodynamic Properties of Intravenously Administered APG-1387 as a Single Agent or In Combinations with systemic Anti-Cancer Agents in Patients with Advanced Solid Tumors or Hematologic Malignancies

Phase I, dose escalation study of ALX148 in patients with advanced solid tumors or lymphoma examining safety, pharmacokinetics and tolerability. NOW IN COMBINATION PHASE II WITH PEMBROLIZUMAB, RITUXIMAB AND TRASTUZUMAB

A Phase I Cohort Dose-Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of AVID 200, a Transforming Growth Factor β (TGFβ) Inhibitor, in Patients with Advanced or Metastatic Solid Tumor Malignancies

Phase 1 Study of BDC-1001 as a Single Agent and in Combination with Pembrolizumab in Patients with Advanced and HER2-Expressing Solid Tumors

Phase 1/2a Dose Escalation, Finding and Expansion Study Evaluating Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-Tumor Activity of PF-07104091 as a Single Agent and in Combination Therapy.

A Phase 1/1B Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of PF-07220060 as a Single Agent and As Part of Combination Therapy In Participants With Advanced Solid Tumors.

First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 in subjects with malignant solid tumors

A Phase III Double-Blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Characterized by PTEN deficiency (CAPItello-281)

Principal Investigator: Dr. Eric Batts

For more information on this trial, read its profile on clinicaltrials.gov here.

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation

Principal Investigator: Dr. Manish Sharma

For more information on this trial, read its profile on clinicaltrials.gov here.

Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer

Principal Investigator: Dr. Sreenivasa Chandana

A Randomized Phase II Study of First Cycle Optimization for Regorafenib Treatment Compared to Standard Dose of Regorafenib in Patients with HCC Who Failed Any 1st Line Systemic Treatment and Whom the Physician is Intending to Treat with Regorafenib

Principal Investigator: Dr. Sreenivasa Chandana

For more information on this trial, read its profile on clinicaltrials.gov here.

An Open-label, Randomized, Multicenter, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-Fluorouracil/Leucovorin versus nab-Paclitaxel plus Gemcitabine in Subjects who have not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas (NAPOLI3)

Principal Investigator: Dr. Sreenivasa Chandana

For more information on this trial, read its profile on clinicaltrials.gov here.

A Phase 2/3 Trial to Evaluate Margetuximab in Combination with INCMGA00012 and Chemotherapy or MGD013 and Chemotherapy in Patients with Metastatic or Locally Advanced, Treatment naïve, HER2 Positive Gastric or Gastroesophageal Junction Cancer

Principal Investigator: Dr. Manish Sharma

For more information on this trial, read its profile on clinicaltrials.gov here.

A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Stage I-III Limited Disease Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy

Principal Investigator: Dr. Yuanbin Chen

For more information on this trial, read its profile on clinicaltrials.gov here.

A Phase II Multicenter, Open-Label, Single Arm Study to Determine the Efficacy, Safety and Tolerability of AZD2811 and Durvalumab Combination as Maintenance Therapy After Induction with Platinum-Based Chemotherapy Combined with Durvalumab, for the First-Line Treatment of Patients with Extensive Stage Small-Cell Lung Cancer

Principal Investigator: Dr. Yuanbin Chen

For more information on this study, please visit its profile on the clinicaltrials.gov website here.

Phase 1/2a Dose Escalation, Finding and Expansion Study Evaluating Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-Tumor Activity of PF-07104091 as a Single Agent and in Combination Therapy.

A Phase 1/1B Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of PF-07220060 as a Single Agent and As Part of Combination Therapy In Participants With Advanced Solid Tumors.

A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in adult patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

Principal Investigator: Dr. Yuanbin Chen

For more information on this trial, read its profile on clinicaltrials.gov here.

Phase II, Open-label, Single-arm Study of Berzosertib (M6620) in Combination with Topotecan in Participants with Relapsed Platinum-resistant Small-Cell Lung Cancer

Principal Investigator: Dr. Yuanbin Chen

For more information on this trial, read its profile on clinicaltrials.gov here.

A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome (Higher-Risk MDS)

Principal Investigator: Dr. Brett Brinker

For more information on this trial, read its profile on clinicaltrials.gov here.

Description: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects ≤65 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma

Principal Investigator: Dr. Brett Brinker

For more information on this trial, read its profile on clinicaltrials.gov here.

A Phase 1/2 First-in-human Study of BMS-986258 (anti TIM3) Alone and in Combination with Nivolumab in Advanced Malignant Tumors

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Primary Investigator: Dr. Erin Pettijohn

For more information on this trial, read its profile on clinicaltrials.gov here.

A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant

Principal Investigator: Dr. Erin Pettijohn

For more information on this trial, read its profile on clinicaltrials.gov here.

A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician’s Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelet Counts <50,000/μL)

Principal Investigator: Dr. Brett Brinker

For more information on this trial, read its profile on clinicaltrials.gov here.

An open-Label Study Of ALPN-202 In Subjects With Advanced Malignancies (NEON-1)

A Phase III Double-Blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Characterized by PTEN deficiency (CAPItello-281)

Principal Investigator: Dr. Eric Batts

For more information on this trial, read its profile on clinicaltrials.gov here.

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation

Principal Investigator: Dr. Manish Sharma

For more information on this trial, read its profile on clinicaltrials.gov here.

Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer

Principal Investigator: Dr. Sreenivasa Chandana

Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Solid Tumors from twelve primary cancer diagnoses: breast, lung, colorectal, prostate, bladder, uterine, kidney and renal pelvis, pancreatic, liver, stomach, ovarian, esophageal

Principal Investigator: Dr. Chandana

For more information on this trial, read its profile on clinicaltrials.gov here.

First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 in subjects with malignant solid tumors